Overview

CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)

Status:
Unknown status

Trial end date:
2010-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the relationship between the side effects(especially arthralgia and arthritis) which appear in the patients who are prescribed aromatase inhibitor(AI) and the CYP19 genetic polymorphisms.

Details

Lead Sponsor:

Korea University Anam Hospital

Collaborator:

Korea University

Treatments:

Anastrozole
Aromatase Inhibitors
Letrozole